CognitMarket market news, portfolio research, and investor insights

Investing.com -- Defense technology provider Anduril Industries has secured a major U.S. Army contract worth up to $1.8 billion over five years to scale its Next-Generation Command and Control (NGC2) system across military operations. The award begins with an initial $162.8 million base period to deploy the software-driven architecture, starting with America’s I Corps in the Pacific theater.

The contract marks a critical transition for the defense program, moving NGC2 from division-level field prototyping to full operational deployment. Under the framework, Anduril's proprietary Lattice software serves as the distributed common data layer, integrating disparate sensors, weapons systems, and warfighting applications into a unified operational network.

The defense contractor previously demonstrated the capabilities of the platform during rigorous multi-service field exercises with the 4th Infantry Division. During these trials, the common architecture connected more than 2,500 end-user

Investing.com -- Intel shares fell over 4% in premarket trading Monday after reports emerged that TSMC is in discussions with Elon Musk's Terafab venture about a potential collaboration — a development that raises questions about Intel's position as the only previously named manufacturing partner at the Texas semiconductor project.

Intel joined Terafab in April 2026, with its next-generation 14A node designated as the facility's sole named process technology.

Meanwhile, TSMC's NYSE-listed ADR climbed 1% after Elon Musk confirmed over the weekend that discussions with the Taiwanese chipmaker about his Terafab semiconductor venture in Texas are ongoing. Taiwan-listed shares closed up 3% on Monday.

Musk posted on X on Sunday, October 4, that the talks are real but early: "Just discussions, but something may come of it." His confirmation followed an exclusive report published Friday, October 2 by the Culpium newsletter, which said TSMC is exploring ways to help Terafab operate its plann

Investing.com -- Cenovus Energy Inc (NYSE: CVE) shares ticked down 1.5% in premarket trading Monday following the company's announcement of a definitive arrangement agreement to acquire Athabasca Oil Corp (TSX: ATH) in a cash and stock transaction with an implied enterprise value of $5.7 billion.

Under the terms of the agreement, Cenovus will acquire all issued and outstanding common shares of Athabasca at $12.00 per share. Each Athabasca shareholder will have the option to elect to receive $12.00 in cash, 0.264 of a Cenovus common share, or a combination of both. The aggregate consideration will comprise between 65% and 75% cash and between 25% and 35% Cenovus shares.

The acquisition adds approximately 45 thousand barrels of oil equivalent per day, including thermal production near Cenovus's Christina Lake, May River and Thornbury assets. The transaction includes high-quality oil sands assets at Leismer and Corner, with over 75 years of proved plus probable reserves life based on es

Investing.com -- Vistra Corp stock rallied 3.5% in pre-open trading today after reports emerged that the Trump administration is set to extend a roughly $4 billion federal loan package to fund capacity upgrades at three of the company’s nuclear power plants — two in Ohio and one in Pennsylvania.

U.S. Energy Secretary Chris Wright was scheduled to formally announce the financing during a planned visit to Vistra’s Perry nuclear complex northeast of Cleveland, lending the news significant official weight and driving pre-market buying interest.

The nuclear loan story broke late last week and carried strong momentum into today’s session. The financing would fund power "uprates" at Vistra’s Perry and Davis-Besse plants in Ohio and its Beaver Valley facility in Pennsylvania — a process that increases output from existing reactors without requiring new licenses, making it faster and less capital-intensive than building new capacity.

The broader policy backdrop amplifies the catalyst: the ad

In this article

Brazilians will decide in just under three weeks whether to re-elect incumbent president Luiz Inácio Lula da Silva or oust him with Flávio Bolsonaro — the son of former president Jair Bolsonaro — as both advanced to a run-off after receiving the most votes in the first round vote on Sunday.

But the results of the first round are recalibrating how investors are pricing what the final decision will be.

Speculators on prediction market platform Kalshi now give Bolsonaro a more than 80% chance of winning the presidency. Before Sunday’s first round results came in, he had about a 60% chance to win. On Polymarket, Bolsonaro’s odds are now 85%, jumping from 63% before the first round count.

While Bolsonaro was seen as a narrow favorite to win the presidency before Sunday’s first round, he was widely expected to trail the incumbent Lula in that initial tally, according to pre-election polls. This was the case even as Bolsonaro was favored to win a run-off. However, Bolsonar

Investing.com -- Alvotech SA (NASDAQ: ALVO) shares jumped 13.5% Monday after the U.S. Food and Drug Administration approved a supplement to the Biologics License Application for AVT02, enabling the company to manufacture the drug substance in a second production suite at its Reykjavik facility.

The approval allows Alvotech to produce AVT02 (adalimumab-ryvk), marketed in the U.S. as SIMLANDI, in either of two drug substance suites at the Reykjavik site. The addition of the second suite, DSM2, effectively doubles the drug substance manufacturing capacity available to support U.S. supply and provides greater flexibility for commercial operations.

The approval follows the FDA's July closure of its most recent inspection of the Reykjavik facility with a Voluntary Action Indicated classification, further confirming resolution of inspection-related matters at the site.

"This approval is important both operationally and as a further regulatory milestone for our Reykjavik facility," said Lis